But even as experts began collecting drug data, Molnupirvir, which halved the risk of death or hospitalization for 775 “at-risk” adults, some said there was a potential negative side to admitting the drug, which was not the Food and Drug Administration. Approved or approved by
The widespread availability of a pill that can prevent the worst consequences of the Covid-1 infection could keep some vaccine holders in a position to refuse shots, they say.
“Perhaps it’s possible that if some people voluntarily take refuge that they are infected, a pill can be found that can help them avoid serious illness,” said Drs. Department of Diseases.
“We see it has already happened through monoclonal antibody treatment,” he said. Treatment, in some cases, administered intravenously and subcutaneously, is indicated for those with mild to moderate COVID-19 cases who are at high risk for serious disease. He said some people may be hesitant about the vaccine because of the existence of these treatments, the idea that they do not necessarily need the vaccine.
As everyone said, the possibility of Molnupirvi in the anti-epidemic arsenal makes Schaffner “90% excited” but “10% concerned” about people who may rely on drugs instead of vaccines. “It’s not a magic pill,” he said.
The pill can be an easy way to help patients and relieve healthcare providers, easily distributed, through easily administered pills. “That’s wonderful, but it doesn’t replace the vaccine,” he said.
An investor note in RBC Capital Markets called Molnupirvi’s data “impressive” and said the drug could “help change the course of the epidemic.”
Yet at one point it echoed Schaffner’s concerns.
Although the option of taking an effective oral medication may reduce the use of “more suspicious therapies” among risky and unresponsive people, “we acknowledge that the availability of this therapy may disrupt vaccines and booster shots,” the note said.
Which did not respond to a request for comment, saying it would soon submit information to the Food and Drug Administration for approval of emergency use.
“With these impressive results, we are hopeful that Molnupirvi could become an important drug as part of a global effort to combat the epidemic,” Merck CEO and President Robert Davis said in a statement Friday morning.
The news of Molnupirvir’s results comes when the vaccination mandate plays a big role in American life and work, putting pressure on those who have not yet received their shots.
The Biden administration is working on a rule that requires at least 100 private sector employers to vaccinate their employees or face regular examinations. Meanwhile, high-profile employers such as hospitals, long-term care providers and even United Airlines UAL,
Preparing for the expulsion of workers.
On the same day that Mark / Ridgeback Therapeutics was announced, California announced the country’s first statewide vaccination mandate for public and private school children.
According to the US Centers for Disease Control and Prevention, only 20% of the American adult population has not yet received a single dose of the vaccine.
According to Dr. G. Gregory Poland, professor of medicine and infectious diseases at the Mayo Clinic, there will be “absolutely” people who choose antiviral pills instead of vaccines.
“Americans, in general, will take no magic pills, but not vaccines,” which have been studied in much more intensive doses, he said.
Poland, director of the Mayo Clinic’s Vaccine Research Group, said the flu season begins with a dynamic every year when looking for something like Tamiflu to help those who don’t have a flu shot.
Even if the FDA approves Malnupirvir, it will take time – and workplace orders and other pressures could further shrink the share of vaccinated people in that time period, he said.
He added that it can be very expensive for people to buy drugs instead of vaccines, which is free. America has already ordered 1.7 million drug treatment courses, costing about 70 705 per five-day treatment course, although this price is not out of pocket for patients to pay.
Poland, like Schaffner, sees the announcement as good news. “I think the more tools there are in the tool kit, the better,” he added, however. “Anyone who thinks it’s a coronavirus answer is sadly wrong. He said.
The stock market ended strong on Friday, with the Dow rising nearly 500 points, according to Merk. Mark’s share has been up more than 4% since the beginning of the year. At the same time, the Dow Jones Industrial Average DJIA,
Was over 12% and the S&P 500 SPX,